Hepatocellular carcinoma chemotherapeutic agents: Efficacy and mode of action

Oncology Reviews

Volumn 8, Issue 1, 2014, Pages

  Shaaban, Saad ^a   Negm, Amr ^b   Ibrahim, Elsayed E ^a   Elrazak, Ahmed A ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b Mansoura University   (Egypt)

Author keywords

Chemoresistance; Hepatocellular carcinoma; Liver cancer; Molecular therapies

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; OCTREOTIDE; RECOMBINANT INTERFERON; SORAFENIB; TAMOXIFEN; THALIDOMIDE; THYMOSIN ALPHA1;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY;

EID: 84903845938     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.4081/oncol.2014.246     Document Type: Review

References (151)

1. Alves, R.C., et al., Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol, 2011. 10[1]: p. 21-7.
2. Bosch, F.X., et al., Primary liver cancer: worldwide incidence and trends. Gastroenterology, 2004. 127[5 Suppl 1]: p. S5-S16. (Pubitemid 39423365)
3. Whittaker, S., R. Marais, and A.X. Zhu, The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010. 29[36]: p. 4989-5005.
4. Blum, H.E., Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol, 2005. 11[47]: p. 7391-400. (Pubitemid 43126017)
5. Rutman, R.J., A. Cantarow, and K.E. Paschkis, Studies in 2-acetylaminofluorene carcinogenesis. I. The intracellular distribution of nucleic acids and protein in rat liver. Cancer Res, 1954. 14[2]: p. 111-4.
6. Kaseb, A.O., et al., Modified cisplatin/interferon alpha-2b/doxorubicin/ 5-fluorouracil [PIAF] chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer, 2013. 119[18]: p. 3334-42.
7. Yang, T.S., et al., Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2000. 89[4]: p. 750-6.
8. Hung, C.S., et al., Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Ann Surg Oncol, 2012. 19[8]: p. 2744-52.
9. Li, T., et al., Aspirin enhances IFN-alpha-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. Cancer Gene Ther, 2013. 20[6]: p. 366-74.
10. Song do, S., et al., Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol, 2013. 19[29]: p. 4679-88.
11. Kodama, Y., et al., Absorption and distribution characteristics of 5-fluorouracil [5-FU] after an application to the liver surface in rats in order to reduce systemic side effects. Biol Pharm Bull, 2008. 31[5]: p. 1049-52. (Pubitemid 351732011)
12. Liu, Y., L. Jiang, and Y. Mu, Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncology letters, 2013. 6[3]: p. 821-828.
13. Marra, M., et al., Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med, 2011. 9[1]: p. 171.
14. Ji, X.-Q., et al., Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Medical science monitor: international medical journal of experimental and clinical research, 2011. 17[8]: p. RA169.
15. Samonakis, D.N., et al., Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Digestive diseases and sciences, 2008. 53[9]: p. 2359-2365.
16. Samonakis, D.N., et al., Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncology reports, 2002. 9[4]: p. 903-907.
17. Li, S., Y. Liu, and Z. Shen, Characterization of Somatostatin Receptor 2 and 5 Expression in Operable Hepatocellular Carcinomas. Hepato-gastroenterology, 2012. 59[119]: p. 2054-2058.
18. Hua, Y.-P., et al., Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy, 2009. 55[5]: p. 312-320.
19. Jia, W.-D., et al., Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. Journal of Cancer Research and Clinical Oncology, 2003. 129[6]: p. 327-334. (Pubitemid 36963194)
20. Liu, H.-L., L. Huo, and L. Wang, Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta pharmacologica Sinica, 2004. 25: p. 1380-1386. (Pubitemid 39361813)
21. Siveke, J., C. Folwaczny, and C. Herberhold, Complete regression of advanced HCC with long acting octreotide. Gut, 2003. 52[10]: p. 1531-1531.
22. Leung, T.W. and P.J. Johnson. Systemic therapy for hepatocellular carcinoma. in Seminars in oncology. 2001. Elsevier.
23. Mansour, A., et al., Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz[α]anthracene and decreases cell proliferation: comparison with tamoxifen. Journal of Cancer Research and Clinical Oncology, 2012. 138[9]: p. 1579-1596.
24. Becker, S., et al., Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. Nuclear medicine and biology, 2010. 37[7]: p. 777-784.
25. Doffoël, M., et al., Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients [Fédé ration Francophone de Cancérologie Digestive 9402]. European journal of cancer [Oxford, England : 1990], 2008. 44[4]: p. 528-538.
26. Barbare, J.-C., et al., Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2005. 23[19]: p. 4338-4346. (Pubitemid 46207007)
27. Guo, R., et al., Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2. Biomedicine & Pharmacotherapy, 2010. 64[4]: p. 249-253.
28. Guo, R., et al., Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression. Biomedicine & Pharmacotherapy, 2009. 63[5]: p. 375-379.
29. Di Maio, M., et al., Is human hepatocellular carcinoma a hormone-responsive tumor? World journal of gastroenterology: WJG, 2008. 14[11]: p. 1682.
30. Chow, P.K., et al., High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology, 2002. 36[5]: p. 1221-1226. (Pubitemid 35253439)
31. Gallo, C., et al., Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC cancer, 2006. 6[1]: p. 196.
32. Ang, S.-F., et al., Activity of Thalidomide and Capecitabine in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology, 2012. 35[3]: p. 222-227 10.1097/COC.0b013e31820dbf56.
33. Chen, Y.-Y., et al., Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis. World journal of gastroenterology: WJG, 2012. 18[5]: p. 466.
34. Feng, Y.-M., et al., Unexpected remission of hepatocellular carcinoma [HCC] with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. BMJ case reports, 2012. 2012.
35. Shao, Y.-Y., et al., Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology, 2012. 82[1]: p. 59-66.
36. Pinter, M., et al., Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. European Journal of Gastroenterology & Hepatology, 2008. 20[10]: p. 1012-1019 10.1097/MEG.0b013e3283036740.
37. Torimura, T., et al., Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma. Translational oncology, 2013. 6[5]: p. 511.
38. Ali, A., et al., Negative Chronotropic Effects and Coronary Ischaemic Abnormalities Following Thalidomide Therapy. Cardiology, 2013. 125[1]: p. 34-37.
39. Kawamura, Y., et al., Common nature in the effects of thalidomide on embryo-fetal development in Kbl:JW and Kbl:NZW rabbits. Congenital Anomalies, 2013: p. n/a-n/a.
40. Jasielec, J.K. and A.J. Jakubowiak, Current approaches to the initial treatment of symptomatic multiple myeloma. International Journal, 2013. 2[1]: p. 61-70.
41. Morabito, F., et al., Bortezomib, Melphalan, Prednisone [VMP] versus Melphalan, Prednisone, Thalidomide [MPT] in elderly newly diagnosed Multiple Myeloma patients: A retrospective case-matched study. American journal of hematology, 2013.
42. Hsu, C., et al., Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology, 2003. 65[3]: p. 242-249. (Pubitemid 37505832)
43. Patt, Y.Z., et al., Thalidomide in the treatment of patients with hepatocellular carcinoma. Cancer, 2005. 103[4]: p. 749-755. (Pubitemid 40216403)
44. Yau, T., et al., Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology, 2007. 72[Suppl. 1]: p. 67-71. (Pubitemid 350256667)
45. Chiou, H.-E., et al., Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2006. 12[43]: p. 6955.
46. Zhang, Z.-l., Z.-s. Liu, and Q. Sun, Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice. CHINESE MEDICAL JOURNAL-BEIJING-ENGLISH EDITION-, 2005. 118[20]: p. 1688.
47. George, P.M., et al., Pharmacology and therapeutic potential of interferons. Pharmacol Ther, 2012. 135[1]: p. 44-53.
48. Hayashi, N. and T. Takehara, Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol, 2006. 41[1]: p. 17-27.
49. Zhuang, L., et al., Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One, 2013. 8[9]: p. e61361.
50. Darnell, J.E., Jr., I.M. Kerr, and G.R. Stark, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994. 264[5164]: p. 1415-21. (Pubitemid 24217131)
51. Ihle, J.N., et al., Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci, 1994. 19[5]: p. 222-7. (Pubitemid 24187246)
52. Shiratori, Y., et al., Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med, 2005. 142[2]: p. 105-14.
53. Nishiguchi, S., et al., Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet, 2001. 357[9251]: p. 196-7. (Pubitemid 32108094)
54. Herzer, K., et al., IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res, 2009. 69[3]: p. 855-62.
55. Zhang, T., et al., Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett, 2010. 290[2]: p. 204-10.
56. Chawla-Sarkar, M., et al., Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis, 2003. 8[3]: p. 237-49. (Pubitemid 36749609)
57. Albini, A., et al., Inhibition of angiogenesis and vascular tumor growth by interferonproducing cells: A gene therapy approach. Am J Pathol, 2000. 156[4]: p. 1381-93. (Pubitemid 30660014)
58. Wu, W.Z., et al., Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol, 2005. 131[3]: p. 169-78.
59. Ikeda, K., et al., Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer, 1998. 82[5]: p. 827-35. (Pubitemid 28104160)
60. Yang, J.Q., et al., Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol, 2008. 14[36]: p. 5564-9; discussion 5568.
61. Liu, Y., et al., Interferon-alpha sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-kappaB activation. Virol J, 2013. 10: p. 168.
62. Nakanishi, C. and M. Toi, Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer, 2005. 5[4]: p. 297-309. (Pubitemid 40488635)
63. Murata, M., et al., A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine, 2006. 33[3]: p. 121-8.
64. Wang, L., et al., High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology, 2000. 32[1]: p. 43-8. (Pubitemid 30432364)
65. Shen, Y.C., et al., Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2013. 2[3-4]: p. 345-364.
66. Welker, M.W. and J. Trojan, Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res, 2013. 5: p. 337-347.
67. Finn, R.S., Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer, 2012. 1[3-4]: p. 247-256.
68. Grem, J.L., 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs, 2000. 18[4]: p. 299-313.
69. Wohlhueter, R.M., R.S. McIvor, and P.G. Plagemann, Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol, 1980. 104[3]: p. 309-19. (Pubitemid 11127508)
70. He, Y.F., et al., Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J Clin Pharm Ther, 2008. 33[3]: p. 307-14.
71. Longley, D.B., et al., The interaction of thymidylate synthase expression with p53- regulated signaling pathways in tumor cells. Semin Oncol, 2003. 30[3 Suppl 6]: p. 3-9. (Pubitemid 36712853)
72. Parker, W.B. and Y.C. Cheng, Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther, 1990. 48[3]: p. 381-95.
73. Zhang, N., et al., 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules, 2008. 13[8]: p. 1551-69.
74. Kojiro, S., et al., Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. J Gastroenterol Hepatol, 2006. 21[1 Pt 1]: p. 129-37.
75. Houghton, J.A., D.M. Tillman, and F.G. Harwood, Ratio of 2'-deoxyadenosine-5'- triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res, 1995. 1[7]: p. 723-30.
76. Yoshioka, A., et al., Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridineinduced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem, 1987. 262[17]: p. 8235-41.
77. Longley, D.B., D.P. Harkin, and P.G. Johnston, 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 2003. 3[5]: p. 330-8. (Pubitemid 37328853)
78. Noordhuis, P., et al., 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol, 2004. 15[7]: p. 1025-32. (Pubitemid 39089778)
79. Cheng, M., et al., 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One, 2012. 7[10]: p. e47115.
80. van der Wilt, C.L., et al., The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat. Eur J Cancer, 1995. 31A[5]: p. 754-60.
81. Eastman, A., The Mechanism of Action of Cisplatin: From Adducts to Apoptosis, in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, B. Lippert, Editor 2006, Verlag Helvetica Chimica Acta: Zürich.
82. Gately, D.P. and S.B. Howell, Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer, 1993. 67[6]: p. 1171-6. (Pubitemid 23172848)
83. Andrews, P.A. and S.B. Howell, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 1990. 2[2]: p. 35-43. (Pubitemid 20218552)
84. Perez, R.P., Cellular and molecular determinants of cisplatin resistance. Eur J Cancer, 1998. 34[10]: p. 1535-42. (Pubitemid 28446333)
85. Jamieson, E.R. and S.J. Lippard, Structure, Recognition, and Processing of Cisplatin- DNA Adducts. Chem Rev, 1999. 99[9]: p. 2467-98.
86. Sorenson, C.M. and A. Eastman, Influence of cis- diamminedichloroplatinum[II] on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res, 1988. 48[23]: p. 6703-7. (Pubitemid 19012192)
87. Mu, D., D.S. Hsu, and A. Sancar, Reaction mechanism of human DNA repair excision nuclease. J Biol Chem, 1996. 271[14]: p. 8285-94. (Pubitemid 26108661)
88. Yamada, M., et al., Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res, 1997. 25[3]: p. 491-6.
89. Zamble, D.B., and Lippard, S. J., The Response of Cellular Proteins to Cisplatin- Damaged DNA, in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, B. Lippert, Editor 2006, Verlag Helvetica Chimica Acta: Zürich.
90. Bruhn, S.L., et al., Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci U S A, 1992. 89[6]: p. 2307-11.
91. Hughes, E.N., B.N. Engelsberg, and P.C. Billings, Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. J Biol Chem, 1992. 267[19]: p. 13520-7.
92. Mini, E., et al., Cellular pharmacology of gemcitabine. Ann Oncol, 2006. 17 Suppl 5: p. v7-12.
93. Venook, A.P., et al., Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol, 2000. 18[14]: p. 2780-7. (Pubitemid 30463562)
94. Heinemann, V., et al., Comparison of the cellular pharmacokinetics and toxicity of 2',2'- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res, 1988. 48[14]: p. 4024-31.
95. Wang, L., et al., Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett, 1999. 443[2]: p. 170-4. (Pubitemid 29078626)
96. Heinemann, V., et al., Cellular elimination of 2',2'- difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res, 1992. 52[3]: p. 533-9.
97. Burris, H.A., 3rd, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997. 15[6]: p. 2403-13.
98. Graziadei, I., et al., Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells. J Hepatol, 1998. 28[3]: p. 504-9. (Pubitemid 28133556)
99. Lin, S., et al., MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int, 2013. 13[1]: p. 3.
100. Wang, W., et al., Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther, 2011. 12[3]: p. 229-38.
101. Huang, P., et al., Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res, 1991. 51[22]: p. 6110-7.
102. Gandhi, V., et al., Excision of 2',2'-difluorodeoxycytidine [gemcitabine] monophosphate residues from DNA. Cancer Res, 1996. 56[19]: p. 4453-9. (Pubitemid 26330454)
103. Heinemann, V., et al., Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'- difluorodeoxycytidine. Mol Pharmacol, 1990. 38[4]: p. 567-72. (Pubitemid 20356209)
104. Plunkett, W., P. Huang, and V. Gandhi, Preclinical characteristics of gemcitabine. Anticancer Drugs, 1995. 6 Suppl 6: p. 7-13. (Pubitemid 26014890)
105. Ruiz van Haperen, V.W., et al., 2',2'-Difluoro-deoxycytidine [gemcitabine] incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol, 1993. 46[4]: p. 762-6.
106. Palmieri, G., et al., Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. International Journal of Oncology, 1996. 8[4]: p. 827-832. (Pubitemid 26111287)
107. Dollinger, M., et al., Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC cancer, 2010. 10[1]: p. 1-11.
108. Dollinger, M.M., et al., Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC cancer, 2008. 8[1]: p. 72.
109. Dollinger, M., et al., Thymostimulin in advanced hepatocellular carcinoma: A phase II trial. BMC cancer, 2008. 8[1]: p. 1-8.
110. Walko, C.M. and C. Lindley, Capecitabine: a review. Clin Ther, 2005. 27[1]: p. 23-44. (Pubitemid 40347299)
111. Wong, M., S.P. Choo, and E.H. Tan, Travel warning with capecitabine. Ann Oncol, 2009. 20[7]: p. 1281.
112. Baird, R., et al., Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. Br J Cancer. 104[1]: p. 43-50.
113. Arcamone, F., et al., Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng, 1969. 11[6]: p. 1101-10.
114. Weiss, R.B., The anthracyclines: will we ever find a better doxorubicin? Semin Oncol, 1992. 19[6]: p. 670-86. (Pubitemid 23004844)
115. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol, 1999. 57[7]: p. 727-41. (Pubitemid 29094544)
116. Lipscomb, L.A., et al., Water ring structure at DNA interfaces: hydration and dynamics of DNA-anthracycline complexes. Biochemistry, 1994. 33[12]: p. 3649-59. (Pubitemid 24116014)
117. Zunina, F., R. Gambetta, and A. Di Marco, The inhibition in vitro of DNA polymerase and RNA polymerases by daunomycin and adriamycin. Biochem Pharmacol, 1975. 24[2]: p. 309-11.
118. Bodley, A., et al., DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res, 1989. 49[21]: p. 5969-78. (Pubitemid 19274156)
119. Tewey, K.M., et al., Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 1984. 226[4673]: p. 466-8. (Pubitemid 14012819)
120. Wassermann, K., et al., Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol, 1990. 38[1]: p. 38-45. (Pubitemid 20231484)
121. Guano, F., et al., Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol, 1999. 56[1]: p. 77-84. (Pubitemid 29309814)
122. Perego, P., et al., Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem, 2001. 8[1]: p. 31-7.
123. Hickman, E.S., M.C. Moroni, and K. Helin, The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev, 2002. 12[1]: p. 60-6. (Pubitemid 34094991)
124. Robles, A.I., X.W. Wang, and C.C. Harris, Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene, 1999. 18[33]: p. 4681-8. (Pubitemid 29417743)
125. Minotti, G., Reactions of adriamycin with microsomal iron and lipids. Free Radic Res Commun, 1989. 7[3-6]: p. 143-8. (Pubitemid 19282475)
126. Pawlowska, J., et al., Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res, 2003. 13[5]: p. 245-52. (Pubitemid 38166378)
127. Nohl, H., L. Gille, and K. Staniek, The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C, 1998. 53[3-4]: p. 279-85. (Pubitemid 28214237)
128. Vasquez-Vivar, J., et al., Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry, 1997. 36[38]: p. 11293-7. (Pubitemid 27408610)
129. Minotti, G., et al., The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J, 1998. 12[7]: p. 541-52. (Pubitemid 28183513)
130. Miyamoto, Y., et al., Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem, 2003. 384[4]: p. 567-74. (Pubitemid 36609172)
131. Wang, S., et al., Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J, 2002. 367[Pt 3]: p. 729-40.
132. Varadwaj, P., et al., Mitoxantrone: an agent with promises for anticancer therapies. Electronic Journal of Biology, 2010. 6[2]: p. 36-42.
133. Shenkenberg, T.D. and D.D. Von Hoff, Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med, 1986. 105[1]: p. 67-81. (Pubitemid 16097929)
134. Fox, E.J., Mechanism of action of mitoxantrone. Neurology, 2004. 63[12 Suppl 6]: p. S15-8. (Pubitemid 40019273)
135. Xia, C., et al., Intercalation of Pharmorubicin Anticancer Drug to DNA Studied by Cyclic Voltammetry with Analytical Applications. Analytical Letters, 1999. 32[4]: p. 717-727.
136. Seitz, S.J., et al., Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer, 2010. 126[9]: p. 2049-66.
137. Hajihassan, Z. and A. Rabbani-Chadegani, Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins. J Biomed Sci, 2009. 16: p. 31.
138. Ehninger, G., et al., Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet, 1990. 18[5]: p. 365-80. (Pubitemid 20134543)
139. Stewart, D.J., et al., Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep, 1986. 70[11]: p. 1255-61. (Pubitemid 17184289)
140. Zhang, X., et al., Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Biomaterials, 2012. 33[29]: p. 7103-14.
141. Zhou, Q., et al., A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine, 2009. 5[4]: p. 419-23.
142. Pfizer, PHARMORUBICIN® product monograph, 2005: Kirkland, Quebec.
143. Pfizer, ELLENCE® product monograph, 2005: New York.
144. Xia, L., et al., miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer, 2008. 123[2]: p. 372-9. (Pubitemid 351842022)
145. Wang, N., et al., MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 12[1]: p. 119.
146. Song, G., et al., Association of p53 with Bid induces cell death in response to etoposide treatment in hepatocellular carcinoma. Curr Cancer Drug Targets, 2009. 9[7]: p. 871-80.
147. Fang P, et al., Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials. PLoS ONE, 2012. 7[12].
148. Finn, R.S., et al., Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver International, 2009. 29[2]: p. 284-290.
149. Ong, L.-C., et al., Effective inhibition of xenografts of hepatocellular carcinoma [HepG2] by rapamycin and bevacizumab in an intrahepatic model. Molecular Imaging and Biology, 2009. 11[5]: p. 334-342.
150. ZUSTOVICH, F., et al., Bevacizumab as Front-line Treatment of Brain Metastases from Solid Tumors: A Case Series. Anticancer Research, 2013. 33[9]: p. 4061-4065.
151. Siegel, A.B., et al., Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. Journal of Clinical Oncology, 2008. 26[18]: p. 2992-2998.